IPHA Key Statistics, Chart & Performance
The current stock price of IPHA is 1.95 USD. In the past month the price decreased by -2.01%. In the past year, price increased by 26.62%.
IPHA Latest News, Press Relases and Analysis
IPHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About IPHA
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
INNATE PHARMA SA-SPONS ADR
117 avenue de Luminy, Bp 30191
Marseille PACA 13009 FR
CEO: Mondher Mahjoubi
Employees: 168
Phone: 33430303030
INNATE PHARMA SA-SPONS ADR / IPHA FAQ
What does INNATE PHARMA SA-SPONS ADR do?
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
What is the current price of IPHA stock?
The current stock price of IPHA is 1.95 USD. The price increased by 3.17% in the last trading session.
Does IPHA stock pay dividends?
IPHA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IPHA stock?
IPHA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for INNATE PHARMA SA-SPONS ADR?
INNATE PHARMA SA-SPONS ADR (IPHA) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for IPHA stock?
The Revenue of INNATE PHARMA SA-SPONS ADR (IPHA) is expected to decline by -26.21% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for INNATE PHARMA SA-SPONS ADR?
INNATE PHARMA SA-SPONS ADR (IPHA) has a market capitalization of 179.73M USD. This makes IPHA a Micro Cap stock.
IPHA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IPHA. When comparing the yearly performance of all stocks, IPHA is one of the better performing stocks in the market, outperforming 70.77% of all stocks.
IPHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IPHA. IPHA may be in some trouble as it scores bad on both profitability and health.
IPHA Financial Highlights
Over the last trailing twelve months IPHA reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -30.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.55% | ||
| ROE | -895.24% | ||
| Debt/Equity | 11.55 |
IPHA Forecast & Estimates
9 analysts have analysed IPHA and the average price target is 5.67 USD. This implies a price increase of 190.72% is expected in the next year compared to the current price of 1.95.
For the next year, analysts expect an EPS growth of -32.84% and a revenue growth -26.21% for IPHA